Ghost Tree Capital’s Global Blood Therapeutics GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-60,000
Closed -$1.76M – 54
2021
Q4
$1.76M Buy
+60,000
New +$1.86M 0.63% 41
2020
Q1
– Sell
-33,400
Closed -$2.66M – 64
2019
Q4
$2.66M Buy
+33,400
New +$1.98M 0.51% 43
2019
Q3
– Sell
-300,000
Closed -$15.8M – 52
2019
Q2
$15.8M Hold
300,000
– – 3.27% 10
2019
Q1
$15.9M Buy
300,000
+200,000
+200% +$9.8M 4.15% 6
2018
Q4
$4.1M Buy
100,000
+88,000
+733% +$3.3M 1.49% 23
2018
Q3
$456K Sell
12,000
-230,000
-95% -$10.2M 0.1% 54
2018
Q2
$10.9M Buy
+242,000
New +$11M 3.22% 9
2018
Q1
– Sell
-325,000
Closed -$12.8M – 65
2017
Q4
$12.8M Buy
325,000
+75,000
+30% +$2.8M 3% 8
2017
Q3
$7.76M Buy
+250,000
New +$7.03M 1.65% 23

Other funds holding GBT

Ghost Tree Capital's GBT Position: Q1 2022 in Review

Ghost Tree Capital sold out of Global Blood Therapeutics (GBT) in Q1 2022, closing a stake of 60,000 shares — an estimated $1.76M sold.

Ghost Tree Capital first reported a position in GBT in Q3 2017 and held it in 9 quarters. The position peaked at $15.9M in Q1 2019. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

  • Ghost Tree Capital reported no remaining Global Blood Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ghost Tree Capital sold 60,000 Global Blood Therapeutics shares in Q1 2022, an estimated $1.76M.
  • Ghost Tree Capital first reported a position in Global Blood Therapeutics in Q3 2017 and held it in 9 quarters.
  • Ghost Tree Capital's Global Blood Therapeutics position peaked at $15.9M in Q1 2019.
  • 204 funds tracked by Wall St. Rank held Global Blood Therapeutics as of Q1 2022.

Based on Ghost Tree Capital's 13F filing for Q1 2022, filed 16 May 2022.